Question explored with the scientific record
benefit of 1 mg melatonic/night for sleep
The short version: 1 mg is a reasonable starting dose, but no trial in front of me tested exactly 1 mg in ordinary adult insomnia, and the adult evidence is genuinely mixed.
The best adult data here is a 2022 review that found melatonin shortened subjective sleep onset in long-term insomnia [4], yet a network meta-analysis inside the same review found no evidence melatonin beat placebo on nighttime symptoms or perceived severity [4]. A separate trial in 45-to-60-year-olds on 3 mg found no difference in sleep efficiency, total sleep time, or subjective outcomes versus placebo [4]. So the honest read: it may help you fall asleep a bit faster, and it probably will not transform your sleep.
| Dose tested | Population | Result |
|---|---|---|
| 1–3 mg | Children with autism | Sleep latency fell from ~38 to ~22 min [1] |
| 2 mg slow-release | Elderly insomniacs | Sleep efficiency 83% vs 75% on placebo [3] |
| 3 mg | Adults 45–60, primary insomnia | No objective or subjective benefit [4] |
| 5 mg | Children, sleep-onset insomnia | Sleep onset advanced 75 min vs placebo [2] |
Two things matter for a nightly 1 mg habit. First, dose accuracy: a survey of 20 major brands found actual tablet content ranged from 80% lower to 460% higher than the label [5]. Your 1 mg may not be 1 mg. Second, timing: in one cohort, taking melatonin at a consistent clock time mattered more than the dose, and inconsistent timing blunted the response [6]. Take it at the same time each night, about 30 minutes before bed [1].
My call: worth a short trial at 1 mg for sleep-onset trouble, taken at a fixed time, from a brand you can verify; do not expect it to fix maintenance insomnia, and stop if it does nothing in a few weeks. Confidence: moderate that low-dose melatonin helps sleep onset in some people; low that 1 mg specifically is the tested dose for healthy adults.
Sources used 6
-
Melatonin for Sleep in Children with Autism: A Controlled Trial Examining Dose, Tolerability, and Outcomes
An open-label, dose-escalation pilot trial in 24 children with autism spectrum disorders (ASD) assessed the dose, tolerability, safety, and outcomes of supplemental melatonin over 14 weeks using actigraphy and parent-reported measures, finding dose-related improvements in sleep …
DOI: 10.1007/s10803-011-1418-3 -
Melatonin for Chronic Sleep Onset Insomnia in Children: A Randomized Placebo-Controlled Trial
In children with chronic sleep onset insomnia, 4 weeks of melatonin 5 mg at 6 PM advanced sleep onset, lights-off time and dim light melatonin onset and increased sleep duration versus placebo, without changing sustained attention.
DOI: 10.1177/088307380101600204 -
Improvement of sleep quality in elderly people by controlled-release melatonin
This randomized, double-blind, crossover trial in 12 elderly insomniacs on multiple medications shows that a 2 mg controlled-release melatonin regimen improves sleep quality (higher sleep efficiency and lower wake after sleep onset) compared with placebo, likely by preserving me…
DOI: 10.1016/s0140-6736(95)91382-3 -
Melatonin for the Treatment of Insomnia: A 2022 Update
An updated CADTH review found mixed evidence that melatonin may improve some sleep outcomes in adults with insomnia, with no evidence found for cost-effectiveness or comparison with prescription sedatives, and guideline recommendations are inconsistent.
DOI: 10.51731/cjht.2022.338 -
Melatonin in Circadian Rhythm and Brain Health: Neuroprotective Effects and Therapeutic Potential
This narrative review synthesizes evidence that melatonin regulates circadian rhythms and may benefit insomnia, depression, Alzheimer's, Parkinson's, cerebral ischemia, and brain aging, but many findings come from small trials or animal models and evidence strength varies.
DOI: 10.14336/ad.2026.0119 -
Treatment of isolated REM sleep behavior disorder using melatonin as a chronobiotic
In 209 iRBD patients, clock-timed low-dose melatonin improved RBD symptoms gradually, effects persisted after discontinuation in some, and inadequate timing or co-medication slowed response.
DOI: 10.1111/jpi.12759